SignalXSignalX

HRMY Harmony Biosciences Holdings, Inc.

Q3 2025 10-Q
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Harmony Biosciences Holdings, Inc. Overview

Harmony Biosciences Holdings, Inc. (HRMY) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New clinical trial risk for Pitolisant PWS Phase 3 TEMPO study initiated Q1 2024 after FDA alignment Oct 2023 and Orphan designation Feb 2024
  • • Updated regulatory risk: FDA approved pediatric EDS label June 2024 but denied pediatric cataplexy sNDA; Type A meeting held Oct 2024 with resubmission Q3 2025
+3 more insights

Get deeper insights on Harmony Biosciences Holdings, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.